Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Research & Development: 2022-2025

Historic Research & Development for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $37.7 million.

  • Stoke Therapeutics' Research & Development rose 69.76% to $37.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.7 million, marking a year-over-year increase of 36.76%. This contributed to the annual value of $89.1 million for FY2024, which is 8.39% up from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' Research & Development is $37.7 million, which was up 45.80% from $25.9 million recorded in Q2 2025.
  • Over the past 5 years, Stoke Therapeutics' Research & Development peaked at $37.7 million during Q3 2025, and registered a low of $18.3 million during Q1 2022.
  • For the 3-year period, Stoke Therapeutics' Research & Development averaged around $24.3 million, with its median value being $22.2 million (2024).
  • Data for Stoke Therapeutics' Research & Development shows a peak YoY spiked of 69.76% (in 2025) over the last 5 years.
  • Over the past 4 years, Stoke Therapeutics' Research & Development (Quarterly) stood at $21.1 million in 2022, then rose by 3.41% to $21.8 million in 2023, then grew by 7.55% to $23.4 million in 2024, then soared by 69.76% to $37.7 million in 2025.
  • Its last three reported values are $37.7 million in Q3 2025, $25.9 million for Q2 2025, and $32.7 million during Q1 2025.